Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.77Last Year’s EPS
-3.6Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely positive clinical and strategic narrative: Respag delivered compelling Phase 2b results with durable efficacy, deepening responses (including up to a fivefold increase in EASI-100), a sizable safety database (>1,000 patients; ~381 patient-years), and FDA alignment to proceed to phase 3 (first randomization in June 2026). The company also strengthened its balance sheet with ~ $476M raised since year-end, enabling phase 3 investments. Offsetting factors include substantial ongoing losses (2025 net loss $164.1M), a sharp projected increase in R&D spend in 2026 (guidance $200M–$250M), rising non-cash interest expense, some safety/tolerability signals (ISRs), pending litigation, and multi-year timelines to approval, creating execution and cash-burn risk. On balance, the positive clinical progress and recent financings meaningfully outweigh the near-term financial and execution risks, but investors should monitor phase 3 execution, 2026 burn, and upcoming 52-week AA data and other catalysts.Company Guidance
Positive Phase 2b Clinical Results in Atopic Dermatitis and Alopecia Areata
First positive 2b results reported for Respag (Rezpeg) in atopic dermatitis (AD) and alopecia areata (AA), validating the Treg mechanism and positioning the program as a late-stage novel MOA candidate.
Strong 36-Week Maintenance Durability and Deepening of Response
36-week maintenance AD data showed durable efficacy and deepening responses with continued dosing (monthly or quarterly maintenance), including increases in EASI-75 and EASI-90 and up to a fivefold (~500%) increase in EASI-100 with extended treatment.
Large Safety Database and Favorable Safety Profile
Respag safety database now exceeds 1,000 patients (≈381 patient-years exposure) with a differentiated safety profile reported and no increased risk observed for systemic adverse events such as conjunctivitis, infection, or malignancy.
Regulatory and Developmental Milestones – Phase 3 Ready
Alignment with the FDA on phase 3 dose and trial elements for AD achieved; first Phase 3 patient randomization expected in June 2026, first pivotal data anticipated mid-2028, and goal to submit a BLA in 2029.
Commercial Development Plans – Convenient Dosing and Device Strategy
Respag demonstrated potential for extended monthly/quarterly maintenance dosing and company plans commercial launch in an auto-injector with weight-banded dosing to enable self-administration similar to single-use pen devices.
Strong Cash Position After Financings
Ended 2025 with $245.8M in cash and investments and no debt; since year-end raised approximately $476M net (≈$432M from an offering + ≈$44M from ATM) and expect to end 2026 with ~$400M–$460M in cash, supporting phase 3 investment.
Portfolio Expansion and Additional Programs
Ongoing TrialNet-sponsored phase 2 in new-onset type 1 diabetes (initial data expected in 2027), NKTR-0165 and NKTR-0166 TNFR2 agonist/bispecific programs advancing preclinically with planned IND submissions in 2027, and multiple additional indication opportunities being explored (e.g., asthma, chronic rhinosinusitis, dermatomyositis).
Commercially Relevant Findings: Asthma and Patient-Reported Outcomes
Respag showed statistically significant improvements in ACQ-5 (asthma control) in AD patients with comorbid asthma (including ~75% improvement in patients with uncontrolled asthma at baseline), and demonstrated rapid itch relief and improvements on patient-reported outcomes.
NKTR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NKTR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 12, 2026 | $70.36 | $73.25 | +4.11% |
Nov 06, 2025 | $55.12 | $55.97 | +1.54% |
Aug 07, 2025 | $21.75 | $23.06 | +6.02% |
May 08, 2025 | $9.28 | $8.83 | -4.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nektar Therapeutics (NKTR) report earnings?
Nektar Therapeutics (NKTR) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is Nektar Therapeutics (NKTR) earnings time?
Nektar Therapeutics (NKTR) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NKTR EPS forecast?
NKTR EPS forecast for the fiscal quarter 2026 (Q1) is -1.77.